Andere Sprachen Gan & Lee Pharmaceuticals.

Aktien

603087

CNE100003ZH1

603087

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 30.05.2024			% 5 Tage	% 1. Jan.
48,49 ^CNY	+2,52 %		+2,11 %	-7,90 %

24.04.	Gan & Lee Pharmaceuticals. meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI
24.04.	Gan & Lee Pharmaceuticals. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	24.05.
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	24.04.
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	24.04.
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	26.01.
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12.12.
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	04.12.
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	10.11.
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	09.11.
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30.10.23
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12.10.23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18.09.23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18.09.23
Gan & Lee Pharma Advances Trial of New Insulin Product	13.09.23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18.08.23
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20.07.23
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20.06.23
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	14.06.23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	27.04.23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	30.03.23
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	24.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Gan & Lee Pharmaceuticals.

Aktien

603087

CNE100003ZH1

603087

Andere Sprachen

Filter